Lidocaine Hydrochloride Injection — FDA Drug Shortage

No longer listed by FDA — Hospira, Inc., A Pfizer Company

The FDA lists a drug shortage record for Lidocaine Hydrochloride Injection (injection) from Hospira, Inc., A Pfizer Company with status No longer listed by FDA. The shortage was first posted on Nov 7, 2025.

Shortage details

Status
No longer listed by FDA
Company
Hospira, Inc., A Pfizer Company
Package NDC
0409-4903-34
Dosage Form
Injection
Presentation
Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)"
Initial Posting
Nov 7, 2025

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.